ArticleBMC veterinary research2026
NF-κB/AP-1-mediated expression of the porcine cathelicidin proPMAP-37 suppresses inflammation by neutralizing LPS and inhibiting M1 macrophage polarization.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCathelicidins are short cationic peptides secreted in pro-peptide, characterized by a conserved N-terminal cathelin domain and a diverse C-terminal mature peptide. While the antimicrobial and immunomodulatory properties of mature cathelicidins are well-characterized, whether their precursor forms (pro-forms) possess biological activity remains a subject of debate. Amid the global challenge of antimicrobial resistance (AMR) and the mandate to reduce antibiotic use in livestock, cathelicidins represent promising alternatives for managing bacterial infection in agriculture. However, high production costs hamper their large-scale application. Therefore, elucidating the regulation of expression of porcine myeloid antimicrobial peptide 37 (PMAP-37), investigating the function of its pro-form (proPMAP-37), and developing a cost-effective production strategy are of significant importance for both basic immunology in porcine systems and agricultural applications.
resultsThis study demonstrated that porcine myeloid antimicrobial peptide 37 (PMAP-37) exhibited widespread tissue distribution in disease-susceptible Duroc × Landrace × Yorkshire (DLY) pigs, whereas its constitutive expression level was significantly higher in disease-resistant Tibetan pigs (TB). Furthermore, Escherichia coli K88 (E. coli K88) upregulated PMAP-37 expression in the intestine of DLY pigs. Mechanistic investigations revealed that the induction of PMAP-37 mediated by E. coli K88 depends on NF-κB and AP-1 transcription factors. Importantly, proPMAP-37 (the precursor of PMAP-37) was successfully expressed in a heterologous system and purified to homogeneity. Functional characterization demonstrated negligible hemolytic activity and cytotoxicity toward mammalian cells. Although no direct bactericidal effect was observed in vitro, proPMAP-37 functioned as an immunomodulator. It exhibited high affinity with Lipopolysaccharide (LPS) and inhibited pro-inflammatory M1 macrophage polarization, thereby reducing the expression of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α).
conclusionsThis comprehensive study provides novel insights into the immunological functions of porcine cathelicidins and promotes the industrial development of proPMAP-37 as a novel anti-inflammatory agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.